LIBTAYO (cemiplimab-rwlc) injection. FDA Approved

LIBTAYO (cemiplimab-rwlc) injection can be ordered by patient or doctor, if the drug has not been approved or is not available in your country. Medvitaz Pharma Solutions can help you from India to get best price/cost of LIBTAYO (cemiplimab-rwlc) injection to treat patients with non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression.
Category: .

LIBTAYO (cemiplimab-rwlc) injection, for intravenous use. Initial U.S. Approval: 09/2018

LIBTAYO (cemiplimab-rwlc) injection is a prescription medicine for Skin Cancer treatment.
INDICATIONS AND USAGE
LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
DOSAGE FORMS & STRENGTHS
Injection: 350 mg/7 mL (50 mg/mL) solution in a single-dose vial.
Manufactured By: Regeneron
Prescribing Information URL: Click Here

Access to LIBTAYO (cemiplimab-rwlc) injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.

The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea.

In September 2018, it was approved by the U.S. Food and Drug Administration (FDA) for treating people with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. It was approved for medical use in the European Union in June 2019. It was approved for medical use in Australia in July 2020.

Cemiplimab is the first FDA approval of a medication specifically for advanced cutaneous squamous cell carcinoma (CSCC).

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.